ERBB2 and cancer: ET-NK/T-DM1 showed enhancement of the anticancer effect in SK-BR-3 depending on the E:T ratio, as shown in Figure 5A. In addition, they showed sufficient anticancer effects even at low concentrations in Calu-3, as shown in in Figure 5B. ET-NK/T-DM1 exhibited enhanced anticancer efficacy in HER2-positive cancers due to the HER2-targeting effects of T-DM1 introduced by ED-TM, while no significant cell death was observed in HER2-negative MDA-MB-231 cells.